作者@article {Tubridy466 = {N。Tubridy Behan卖方和r . Capildeo A乔杜里·r·福布斯和C.P.霍金斯R.A. c·休斯和j .宫殿和b Sharrack r .打麻器,c .年轻和I.F.莫斯利D.G. MacManus Donoghue s和d·h·米勒和英国Antegren研究小组},title = {anti-α4的影响整合素抗体对大脑病变活动}女士,体积={53}={3},页面= {466 - 466}= {1999},doi = {10.1212 / WNL.53.3.466},出版商= {Wolters Kluwer健康,公司代表美国神经病学学会},文摘={目的:确定人源化单克隆抗体的影响对α4整合素(无功α4β1整合素或很晚抗原{\ textendash} 4)女士在MRI病灶活动方法:一项随机、双盲、安慰剂对照试验,72年活跃的患者复发缓和和次要进步的女士。首页每个病人接受两种静脉输液anti-α4整合蛋白抗体(natalizumab;Antegren)或安慰剂4周,与串行MRI随访24周和临床评估。结果:治疗组表现出更少的新活动病变(平均1.8和3.6每个病人)和新的增强病变(每个病人平均1.6和3.3)比安慰剂组在头12周。没有显著差异的新的活动或增强病变在第二12周的研究。baseline-enhancing病变(即的数量。病变,提高基线扫描),继续加强第一次治疗后4周两组之间没有明显不同。患者急性发作女士的数量没有明显不同的两组在第一次12周治疗组(9和10安慰剂),但高治疗组在第二个12周(14和3;p = 0.005)。 The study was not, however, designed to look definitively at the effect of treatment on relapse rate. Treatment was well tolerated. Conclusions: Short-term treatment with monoclonal antibody against α4 integrin results in a significant reduction in the number of new active lesions on MRI. Further studies will be required to determine the longer term effect of this treatment on MRI and clinical outcomes.}, issn = {0028-3878}, URL = {//www.ez-admanager.com/content/53/3/466}, eprint = {//www.ez-admanager.com/content}, journal = {Neurology} }